Home » Bio-analytics firm opening $12.5M Louisville facility, creating 110 jobs

Bio-analytics firm opening $12.5M Louisville facility, creating 110 jobs

Will be Eurofins Scientific’s central genomics laboratory in North America

LOUISVILLE, Ky. (March 1, 2016) — Eurofins Scientific, the global leader in bio-analytical testing, and one of the world leaders in genomic services, has opened a new $12.5 million state-of-the-art manufacturing and services facility in Louisville that will include up to 110 new employees, including lab technicians, chemists and biologists as well as positions in customer service, logistics, information technology, administration, finance and accounting.


The 65,800-s.f. facility functions as the Eurofin’s central genomics laboratory in North America, focusing on the custom production of DNA and RNA oligonucleotides synthetic gene synthesis, and genomics services including DNA sequencing, synthetic biology,and next generation sequencing.

Kentucky ranks among the nation’s logistics leaders, located within a day’s drive of two-thirds of the U.S. population and personal income. Nineteen interstates and major highways, 13 freight railroads, 1,490 miles of commercially navigable waterways, five commercial airports and dozens of regional airports make the Commonwealth an ideal location for companies focused on exports.

“We are pleased to welcome Eurofins Scientific to Kentucky and excited about the opportunity to create jobs in the promising career field of genomics right here in Louisville,” said Gov. Matt Bevin. “We are glad they will be taking advantage of the many logistical capabilities that cannot easily be replicated by other states.  It is a testament to the quality of Louisville’s workforce and further indication that Kentucky is open for business.”

The Louisville facility will be one of the newest and most advanced genomics facilities in the world. As a multi-functional hub, the site will also house other activities such as food and microbiology testing, which should foster diversity and synergy between scientific applications of molecular testing.

“Eurofins is a great example of the type of global leader our city wants to attract,” said Louisville Mayor Greg Fischer. “A modern, innovative company that delivers, bringing together two of our five main economic development clusters — logistics, and lifelong wellness and aging care. Our city’s central location, with world-class logistics, will help Eurofins get their products in, tested and returned more efficiently than anywhere else. This is a big win for Louisville as we continue to attract and support leaders in these industries.”

The company will introduce new, proprietary synthesis technology in the new facility, which will lead to increased quality and reliability in its oligonucleotides production capabilities.

To encourage the investment and job growth in the community, the Kentucky Economic Development Finance Authority (KEDFA) preliminarily approved the company for tax incentives up to $2.3 million through the Kentucky Business Investment program. The performance-based incentive allows a company to keep a portion of its investment over the term of the agreement through corporate income tax credits and wage assessments by meeting job and investment targets.

Additionally, KEDFA approved Eurofins for $250,000 in tax incentives through the Kentucky Enterprise Initiative Act (KEIA). KEIA allows approved companies to recoup Kentucky sales and use tax on construction costs, building fixtures, equipment used in research and development and electronic processing equipment.